Overview
EXO Biologics is a Belgian clinical-stage biotech company developing exosome-based biopharmaceuticals for rare diseases with high unmet needs, including respiratory conditions like bronchopulmonary dysplasia (BPD) in preterm newborns. They offer ExoXpert, a specialized CDMO service for exosome development and GMP manufacturing using the ExoPulse platform. Their pipeline targets inflammatory, neurological, and oncological applications, with lead candidate EXOB-001 in Phase 1/2 trials.
Frequently asked questions
- What are EXO Biologics' core capabilities in exosome development?
- EXO Biologics provides an innovative drug loading and delivery platform using exosomes, supported by a state-of-the-art GMP manufacturing platform from research to clinical use via ExoPulse technology.
- What regulatory designations has EXO Biologics received?
- EXOB-001 has Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, Orphan Drug Designation from the EMA, and is in an EMA-authorized Phase 1/2 trial (EVENEW, NCT06279741) for BPD prevention.
- What therapeutic areas and geographies does EXO Biologics serve?
- Focus on rare diseases in respiratory (e.g., BPD), inflammatory bowel, neurology, and oncology; based in Belgium (Liege), conducting trials in Europe (Belgium, Italy), with global CDMO services via ExoXpert.